The abstract is read at the publisher; the summary is JClub's.
Oral oxfendazole (OFN) suppresses osteoclast formation and osteolytic activity in an osteosarcoma tibial orthotopic mouse model, reducing bone resorption without significantly inhibiting tumor growth.
- Why it matters: Osteosarcoma-associated osteolysis is driven by osteoclast–tumor interactions, and existing osteoclast-targeting drugs are insufficient to control osteolytic bone damage and related complications.
- What they did: Single-cell RNA sequencing identified osteoclast differentiation regulators, and Beyondcell drug screening highlighted OFN with ANXA2 as a key associated target; OFN effects were tested by osteoclastogenesis assays and micro-CT/histology, with qRT-PCR and immunohistochemistry for ANXA2.
- The result: OFN downregulates ANXA2 in vitro and in vivo, impairing osteoclast differentiation, and simulations plus validation suggest OFN may interact with ZNF530 to reduce ANXA2 transcription.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.